“The greatest need we have today in the human cancer problem, except for a universal cure, is a method for detecting cancer before there are any clinical signs or symptoms.”
Sidney Farber, M.D.
Father of modern chemotherapy
pioneering the detection of early cancer
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.
A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.
At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer's origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.
Vince Lozada serves as Chief Financial Officer at Harbinger Health where he oversees all financial matters and helps lead the effort to build and scale operations including the clinical lab.
Vince brings almost 20 years of investment banking experience to his role at Harbinger. He most recently served as Managing Director, Healthcare Investment Banking at RBC Capital Markets, where he advised biotechnology companies on mergers, acquisitions, partnerships, and financings, including initial public offerings, common stock offerings, convertible debt offerings and high yield debt offerings. Prior to joining RBC Capital Markets in 2016, Vince spent nine years at Credit Suisse in roles of increasing responsibility within the Healthcare and Technology Mergers & Acquisitions organizations. Earlier in his career, Vince was a member of the Technology Investment Banking team at BofA Securities. He has completed more than 70 strategic and financing transactions valued at approximately $75 billion over the course of his 20 years in the industry. Vince holds an M.B.A. from the University of Chicago’s Booth School of Business and a B.S. in Finance from Rutgers. He is also a Chartered Financial Analyst (CFA) charter holder.
our leadership team
our board of directors
Director, Social & Behavioral Sciences, Community Engagement
Operation Warp Speed
Professor, Department of Gastrointestical Medical Oncology
Chair Department of Investigational Cancer Therapeutics
Chief Quality Officer
Board member, Kaiser Foundation